Cargando…

A comparison of the extended-release and standard-release formulations of tacrolimus in de novo kidney transplant recipients: a 12-month outcome study

BACKGROUND: Limited comparative data are available on the outcomes between extended-release and standard-release tacrolimus when used de novo in kidney transplant recipients (KTRs). METHODS: We identified KTRs transplanted at our institution during 2009–10 routinely prescribed extended-release tacro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fanous, Helen, Zheng, Rebecca, Campbell, Carolyn, Huang, Michael, Nash, Michelle M., Rapi, Lindita, Zaltzman, Jeffrey S., Prasad, G. V. Ramesh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2013
Materias:	Original Contributions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3560378/ https://www.ncbi.nlm.nih.gov/pubmed/23372940 http://dx.doi.org/10.1093/ckj/sfs169

Ejemplares similares

A prospective cohort conversion study of twice-daily to once-daily extended-release tacrolimus: role of ethnicity
por: Glick, Lauren, et al.
Publicado: (2014)

Lower total and percent of high-molecular-weight adiponectin concentration in South Asian kidney transplant recipients
por: Prasad, G. V. Ramesh, et al.
Publicado: (2012)

Serum Apolipoprotein B and A1 Concentrations Predict Late-Onset Posttransplant Diabetes Mellitus in Prevalent Adult Kidney Transplant Recipients
por: Malyala, Rohit, et al.
Publicado: (2019)

The Effect of Intracellular Tacrolimus Exposure on Calcineurin Inhibition in Immediate- and Extended-Release Tacrolimus Formulations
por: Fontova, Pere, et al.
Publicado: (2023)

Efficacy and safety of tacrolimus in de novo pediatric transplant recipients randomized to receive immediate‐ or prolonged‐release tacrolimus
por: Vondrak, Karel, et al.
Publicado: (2019)

The role of CYP3A5 polymorphism and dose adjustments following conversion of twice-daily to once-daily tacrolimus in renal transplant recipients
por: Zaltzman, Alina S. R, et al.
Publicado: (2016)

Once-Daily Tacrolimus Extended-Release Formulation: 1 Year after Conversion in Stable Pediatric Kidney Transplant Recipients
por: Pape, Lars, et al.
Publicado: (2011)

Real-life comparison of efficacy and safety profiles of two prolonged-release tacrolimus formulations in de novo kidney transplant recipients: 24 months of follow-up
por: Czarnecka, Paulina, et al.
Publicado: (2023)

Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation
por: Prasad, G. V. Ramesh, et al.
Publicado: (2019)

Prolonged-Release Once-Daily Formulation of Tacrolimus Versus Standard-of-Care Tacrolimus in de novo Kidney Transplant Patients Across Europe
por: Budde, Klemens, et al.
Publicado: (2022)

Paraoxonase 1 Phenotype and Mass in South Asian versus Caucasian Renal Transplant Recipients
por: Connelly, Philip W., et al.
Publicado: (2012)

Limited sampling strategies for estimation of tacrolimus exposure in kidney transplant recipients receiving extended‐release tacrolimus preparation
por: El‐Nahhas, Toqa, et al.
Publicado: (2021)

A randomized cross-over comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily tacrolimus on renal function in healthy volunteers
por: Zaltzman, Jeffrey S, et al.
Publicado: (2014)

Tacrolimus Intrapatient Variability After Switching From Immediate or Prolonged-Release to Extended-Release Formulation, After an Organ Transplantation
por: Del Bello, Arnaud, et al.
Publicado: (2021)

Additive Manufacturing of an Extended-Release Tablet of Tacrolimus
por: Abdollahi, Azin, et al.
Publicado: (2023)

Population pharmacokinetics of immediate‐ and prolonged‐release tacrolimus formulations in liver, kidney and heart transplant recipients
por: Lu, Zheng, et al.
Publicado: (2019)

Long-Term Follow-Up of a Phase III Clinical Trial Comparing Tacrolimus Extended-Release/MMF, Tacrolimus/MMF, and Cyclosporine/MMF in De Novo Kidney Transplant Recipients
por: Silva, Hélio Tedesco, et al.
Publicado: (2014)

Pre-Transplant Left Ventricular Geometry and Major Adverse Cardiovascular Events After Kidney Transplantation
por: Malyala, Rohit, et al.
Publicado: (2019)

Monthly Extended-Release Risperidone (RBP-7000) in the Treatment of Schizophrenia: Results From the Phase 3 Program
por: Andorn, Anne, et al.
Publicado: (2019)

Comparison of the Impact of Pharmacogenetic Variability on the PK of Slow Release and Immediate Release Tacrolimus Formulations
por: van Gelder, Teun, et al.
Publicado: (2020)

Pharmacokinetics of Prolonged-Release Once-Daily Formulations of Tacrolimus in De Novo Kidney Transplant Recipients: A Randomized, Parallel-Group, Open-Label, Multicenter Study
por: Kamar, Nassim, et al.
Publicado: (2018)

Budget impact of switching from an immediate-release to a prolonged-release formulation of tacrolimus in renal transplant recipients in the UK based on differences in adherence
por: Muduma, Gorden, et al.
Publicado: (2014)

Randomized Controlled Crossover Trials of the Pharmacokinetics of PRC-063, a Novel Multilayer Extended-Release Formulation of Methylphenidate, in Healthy Adults
por: Katzman, Martin A., et al.
Publicado: (2020)

Systematic conversion to generic tacrolimus in stable kidney transplant recipients
por: Rosenborg, Staffan, et al.
Publicado: (2014)

A single-centre comparison of the clinical outcomes at 6 months of renal transplant recipients administered Adoport(®) or Prograf(®) preparations of tacrolimus
por: Connor, Andrew, et al.
Publicado: (2013)

Monitoring Kidney Dysfunction in Kugelberg-Welander Syndrome
por: West, Michael, et al.
Publicado: (2019)

Renal Function in De Novo Liver Transplant Recipients Receiving Different Prolonged‐Release Tacrolimus Regimens—The DIAMOND Study
por: TruneČka, P., et al.
Publicado: (2015)

Effectiveness and safety of the conversion to MeltDose(®) extended‐release tacrolimus from other formulations of tacrolimus in stable kidney transplant patients: A retrospective study
por: Sánchez Fructuoso, Ana, et al.
Publicado: (2019)

Pharmacokinetics of Once‐Daily Extended‐Release Tacrolimus Tablets Versus Twice‐Daily Capsules in De Novo Liver Transplant
por: DuBay, Derek A., et al.
Publicado: (2019)

Retrospective Analysis of Tacrolimus Intrapatient Variability as a Measure of Medication Adherence
por: Herblum, Jordana, et al.
Publicado: (2021)

Improved Medication Adherence with the Use of Extended-Release Tacrolimus in Liver Transplant Recipients: A Pilot Randomized Controlled Trial
por: Verma, Manisha, et al.
Publicado: (2023)

Conversion From Twice-Daily Tacrolimus Capsules to Once-Daily Extended-Release Tacrolimus (LCPT): A Phase 2 Trial of Stable Renal Transplant Recipients
por: Gaber, A. Osama, et al.
Publicado: (2013)

A single‐center, open‐label, randomized cross‐over study to evaluate the pharmacokinetics and bioavailability of once‐daily prolonged‐release formulations of tacrolimus in de novo liver transplant recipients
por: Herden, Uta, et al.
Publicado: (2021)

Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Lisdexamfetamine in Healthy Adults
por: Faison, Shamia L., et al.
Publicado: (2021)

Model-Based Approach for Establishing the Predicted Clinical Response of a Delayed-Release and Extended-Release Methylphenidate for the Treatment of Attention-Deficit/Hyperactivity Disorder
por: Gomeni, Roberto, et al.
Publicado: (2020)

The effect of tacrolimus conversion from immediate- to extended-release formulation on renal function in renal transplant patients: a meta-analysis
por: Chao, Sheng, et al.
Publicado: (2023)

Extended-release monthly buprenorphine injection
por: Cuperfain, Ari B., et al.
Publicado: (2023)

Characterization of Extended-Release Lorazepam: Pharmacokinetic Results Across Phase 1 Clinical Studies
por: Mathew, Sanjay J., et al.
Publicado: (2023)

A Comparative Analysis of Once-daily and Twice-daily Formulation of Tacrolimus in De Novo Kidney Transplant Recipients
por: Ferhatoglu, Murat Ferhat, et al.
Publicado: (2021)

Sequential Cohort Analysis After Liver Transplantation Shows de Novo Extended Release Tacrolimus Is Safe, Efficacious, and Minimizes Renal Dysfunction
por: Lim, Tiong Yeng, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ijj95fs9pupbaq6uj44i6r3pni